# Clinical Trials Data ERBB2 - Document 47

# Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01344837

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Women with uterine papillary serous carcinoma (UPSC) who were eligible for GOG-0210 protocol, a molecular staging study in endometrial cancer, or GOG-0136, a general specimen banking study for gynecologic cancer, have consented to future research, have histologically-confirmed UPSC of any stage, and have satisfactory formalin-fixed and paraffin-embedded primary tumor with or without a satisfactory pre-operative serum specimen available for testing\n\* Women with endometrioid endometrial cancer who were eligible for GOG-0210 or GOG-0136, have consented to future research, have histologically-confirmed endometrioid endometrial carcinoma with a similar stage, age and race/ethnicity distribution as the UPSC patients, have satisfactory formalin-fixed and paraffin-embedded primary tumor and/or pre-operative serum specimen available for testing\n\* Normal healthy control women who participated in the Biopathology protocol for banking sera from normal healthy control women, have consented to future research, do not have a cancer or a history of cancer and have a similar age and race/ethnicity distribution as the UPSC patients and have satisfactory serum available for testing",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
"stdAges": [  
"CHILD",  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with uterine cancer",

Question:  
Based on the following clinical trial information, would a patient with a ERBB2 gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, the eligibility is primarily determined by the type of cancer and participation in specific protocols, such as GOG-0210 or GOG-0136, rather than specific genetic mutations like ERBB2. Here are the main points from the eligibility criteria:  
  
1. The trial is only open to women with specific types of uterine cancer:  
 - Uterine papillary serous carcinoma (UPSC) who have participated in certain Gynecologic Oncology Group (GOG) protocols.  
 - Endometrioid endometrial carcinoma, also linked to participation in the specified GOG protocols.  
  
2. Participants should have histologically confirmed cancer with satisfactory tissue or serum specimens.  
  
3. There is also a group of normal healthy control women, who have no cancer diagnosis or history of cancer.  
  
The mutation status of the ERBB2 gene is not mentioned as a criterion for eligibility. Therefore, the presence or absence of an ERBB2 mutation does not appear to be a factor in determining eligibility for this study. Eligibility is more dependent on the type of uterine cancer, consent for future research, and participation in specific GOG protocols.